What Can You Do To Overcome Immunogenicity And Immunotoxicity Assessment Challenges?

The last decade in drug development has given rise to many different types of new therapies that offer great potential in improving patient care. However, the increasing complexity of these advanced pharmaceuticals makes it incredibly challenging to bring them to market, with 89% of novel drugs failing human clinical trials.¹ While there are many reasons this could occur, approximately half of these failures were due to unanticipated human toxicity.¹ In rare cases, unwanted immune responses have led to the death of clinical trial participants.²